Atherectomy Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The atherectomy devices market size was valued at USD 1.04 billion in 2025 and estimated to grow from USD 1.12 billion in 2026 to reach USD 1.61 billion by 2031, at a CAGR of 7.58% during the forecast period (2026-2031). This report Segments the Industry Into by Product (Directional Atherectomy Systems, Orbital Atherectomy Systems, Photo-Ablative (Laser) Atherectomy Systems, Rotational Atherectomy Systems), by Application (Peripheral Vascular Applications, Cardiovascular Applications, Neurovascular Applications), by End User (Hospitals and Surgical Centers, Ambulatory Care Centers, and More), and Geography.

Global Atherectomy Devices Market Trends and Insights

Rising Prevalence of Peripheral & Coronary Artery Disease

Peripheral artery disease affects more than 200 million people worldwide, most acutely in aging populations with diabetes and metabolic syndrome. The expanding burden raises procedural complexity because heavily calcified lesions respond poorly to plain balloon angioplasty. Current U.S. and European guidelines now recommend endovascular interventions for infra-inguinal lesions under 25 cm, opening a larger pool of candidates for atherectomy. Hospitals report that older patients present with longer, more complex occlusions that require vessel-preparation techniques to achieve acceptable luminal gain. Consequently, device makers emphasize systems able to debulk eccentric calcium while minimizing embolic events. The long-term demographic tailwind supports double-digit growth in procedure volumes for at least the next decade.

Growing Adoption of Minimally Invasive Endovascular Procedures

Hospitals and outpatient centers prefer shorter stays and quicker ambulation, pushing physicians to select techniques that reduce anesthesia time and wound complications. Medicare reimbursements for OBL interventions reached USD 6.8 billion across 6,308 facilities in 2023. Atherectomy fits this shift because most systems are compatible with 6Fr sheaths, allowing same-day discharge. Ambulatory surgical centers have posted an 8.06% CAGR in atherectomy procedure counts as vascular surgeons and advanced practice providers gain proficiency. Rising comfort among payors with OBL safety metrics further lifts utilization, reinforcing a feedback loop that sustains capital purchases of new systems. Comparable trends in Europe and advanced Asia-Pacific economies are visible albeit at lower absolute volumes.

Limited Long-Term Evidence of Superiority vs. PTA/Stenting

The 2,005-patient ECLIPSE trial reported no statistical advantage for orbital atherectomy over plain balloon angioplasty in preventing target vessel failure before drug-eluting stent implantation00450-7/abstract). This neutral outcome echoes prior peripheral registries in which atherectomy reduced amputation risk yet increased repeat intervention rates. Evidence-based payors may therefore restrict reimbursement to subgroups with demonstrated benefit, constraining volume growth in regions that prioritize randomized data over operator preference.

Other drivers and restraints analyzed in the detailed report include:

• Favorable Reimbursement Incentives for Office-Based Labs (U.S.)
• Laser Systems with Active Aspiration Lower Distal-Embolization Risk
• High Device & Capital Costs for Providers

Segment Analysis

Directional systems generated 41.78% of atherectomy devices market revenue in 2025, reflecting surgeon preference for precise plaque excision and compatibility with post-dilation balloons. The atherectomy devices market size for directional platforms is projected to grow at a steady 7.08% CAGR to 2031 as new cutter-head geometries improve crossing profile without sacrificing debulking capacity. Laser catheters represent the fastest-rising modality at 7.74% CAGR because aspiration-assisted designs significantly lower embolic risk. Rotational and orbital devices remain essential for densely calcified coronary and iliac lesions yet face scrutiny following neutral ECLIPSE outcomes.

Competitive positioning hinges on differentiated burr coatings, real-time feedback algorithms, and bundled service contracts. Abbott’s Diamondback 360 leverages a diamond-embedded crown that orbits eccentrically to sand down calcium, whereas Boston Scientific’s Jetstream incorporates front-cutting blades plus aspiration for in-stent restenosis. University-industry projects such as milli-scale robotics foreshadow next-generation systems capable of remote navigation through tortuous neurovascular beds. FDA guidance on Predetermined Change Control Plans allows manufacturers to pre-specify software updates, shortening iteration cycles and accelerating innovation cadence.

Complete Report Scope:

• By Device Type (Value)
  • Directional Atherectomy Devices
  • Rotational Atherectomy Devices
  • Orbital Atherectomy Devices
  • Laser Atherectomy Devices
• By Application (Value)
  • Peripheral Vascular Disease
  • Coronary Artery Disease
  • Neurovascular Disease
• By End User (Value)
  • Hospitals & Surgical Centers
  • Ambulatory Surgical Centers
  • Office-Based Labs
• by Geography (Value)
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America generated 38.74% of atherectomy devices market revenue in 2025 on the back of high procedural density, entrenched reimbursement, and robust clinical research infrastructure. The region’s growth moderates to mid-single-digit rates as volume shifts from hospital inpatient to outpatient venues. The atherectomy devices market size in Asia-Pacific will expand at an 8.08% CAGR through 2031, underpinned by domestic manufacturing incentives and accelerating cardiovascular disease prevalence. China’s Fourteenth Five-Year Plan calls for local production of high-end interventional devices, positioning regional firms to undercut imports without compromising quality. Japan and South Korea, meanwhile, leverage mature reimbursement systems that now recognize vessel-preparation codes, stimulating early adoption.

Europe remains the third-largest regional segment, characterized by evidence-oriented purchasing committees influenced by the Medical Device Regulation. Hospitals emphasize long-term safety registries; therefore, suppliers that document reduced reintervention rates achieve preferred-vendor status. Innovation uptake is fastest in Germany and the Netherlands where OBL equivalents - practice-based cath labs - operate under bundled diagnosis-related group payments. Latin America and Middle East & Africa collectively account for less than 10% of global sales but show high-single-digit growth as private insurers expand coverage for peripheral vascular procedures.

List of Companies Covered in this Report:

• Abbott Laboratories
• Medtronic
• Boston Scientific
• Koninklijke Philips
• AngioDynamics
• Beckton Dickinson
• Straub Medical
• Avinger Inc.
• Terumo
• Shockwave Medical Inc.
• Cook Group
• Merit Medical Systems
• Penumbra
• BIOTRONIK
• Rex Medical LP
• Ra Medical Systems Inc.
• Cardiovascular Systems Inc. (CSI)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support